{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:12:31Z","timestamp":1758039151192,"version":"3.44.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.ad.2016.12.025","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T04:43:38Z","timestamp":1499921018000},"page":"894-901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Concordancia mutacional de BRAF entre melanoma primario cut\u00e1neo y sus correspondientes met\u00e1stasis. Revisi\u00f3n de la evidencia actual"],"prefix":"10.1016","volume":"108","author":[{"given":"E.","family":"Godoy-Gij\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Yuste-Chaves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1.","family":"Santos-Briz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2016.12.025_bib0300","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/bjs.7562","article-title":"HER-2 status in primary oesophageal cancer, lymph nodes and distant metastases","volume":"98","author":"Schoppmann","year":"2011","journal-title":"Br J Surg"},{"key":"10.1016\/j.ad.2016.12.025_bib0305","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/156800912799095162","article-title":"Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients: Implications for cancer therapy","volume":"12","author":"Cejas","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.ad.2016.12.025_bib0310","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/sj.bjc.6604848","article-title":"Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant","volume":"100","author":"Molinari","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ad.2016.12.025_bib0315","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1200\/JCO.2008.18.7286","article-title":"Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer","volume":"26","author":"Artale","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2016.12.025_bib0320","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1158\/1078-0432.CCR-09-2446","article-title":"Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases","volume":"16","author":"Baldus","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ad.2016.12.025_bib0325","doi-asserted-by":"crossref","first-page":"e8199","DOI":"10.1371\/journal.pone.0008199","article-title":"KRAS mutations in primary colorectal cancer tumors and related metastases: A potential role in prediction of lung metastasis","volume":"4","author":"Cejas","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ad.2016.12.025_bib0330","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1634\/theoncologist.2011-0024","article-title":"Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: A review","volume":"16","author":"Baas","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.ad.2016.12.025_bib0335","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/DCR.0b013e31821d37a3","article-title":"Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer","volume":"54","author":"Watanabe","year":"2011","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ad.2016.12.025_bib0340","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/bjc.2011.26","article-title":"KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients","volume":"104","author":"Knijn","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ad.2016.12.025_bib0345","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1158\/1078-0432.CCR-07-4906","article-title":"K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy","volume":"14","author":"Etienne-Grimaldi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ad.2016.12.025_bib0350","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1200\/JCO.2008.20.2796","article-title":"PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer","volume":"27","author":"Loupakis","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2016.12.025_bib0355","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1634\/theoncologist.2008-0181","article-title":"High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice","volume":"13","author":"Santini","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ad.2016.12.025_bib0360","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/mp.56.3.137","article-title":"Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas","volume":"56","author":"Zauber","year":"2003","journal-title":"Mol Pathol"},{"key":"10.1016\/j.ad.2016.12.025_bib0365","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/0959-8049(92)90468-H","article-title":"Stability of K-ras mutations throughout the natural history of human colorectal cancer","volume":"28A","author":"Losi","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ad.2016.12.025_bib0370","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12253-012-9564-2","article-title":"HER2 status of gastric carcinoma and corresponding lymph node metastasis","volume":"19","author":"Pagni","year":"2013","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.ad.2016.12.025_bib0375","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/1471-2407-12-347","article-title":"Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer","volume":"12","author":"Kim","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ad.2016.12.025_bib0380","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2016.12.025_bib0385","first-page":"6483","article-title":"NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression","volume":"9","author":"Omholt","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ad.2016.12.025_bib0390","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1158\/1078-0432.CCR-1169-3","article-title":"Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas","volume":"10","author":"Shinozaki","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ad.2016.12.025_bib0395","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/sj.bjc.6606072","article-title":"Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression","volume":"104","author":"Lin","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ad.2016.12.025_bib0400","doi-asserted-by":"crossref","first-page":"e29336","DOI":"10.1371\/journal.pone.0029336","article-title":"Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma","volume":"7","author":"Yancovitz","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ad.2016.12.025_bib0405","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ad.2016.12.025_bib0410","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2016.12.025_bib0415","first-page":"6997","article-title":"BRAF and RAS mutations in human lung cancer and melanoma","volume":"62","author":"Brose","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ad.2016.12.025_bib0420","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ad.2016.12.025_bib0425","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00008390-200510000-00011","article-title":"Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases","volume":"15","author":"Kirschner","year":"2005","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ad.2016.12.025_bib0430","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1055-9965.EPI-06-1038","article-title":"Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma","volume":"16","author":"Thomas","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ad.2016.12.025_bib0435","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1479-5876-8-67","article-title":"Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032","volume":"8","author":"Rubinstein","year":"2010","journal-title":"J Transl Med"},{"key":"10.1016\/j.ad.2016.12.025_bib0440","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s12094-013-1090-5","article-title":"Guidelines for biomarker testing in metastatic melanoma: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology","volume":"16","author":"Martin-Algarra","year":"2014","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ad.2016.12.025_bib0445","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.sder.2012.07.007","article-title":"Molecular platforms utilized to detect BRAF V600E mutation in melanoma","volume":"31","author":"Curry","year":"2012","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.ad.2016.12.025_bib0450","first-page":"756","article-title":"Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation","volume":"63","author":"Satyamoorthy","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ad.2016.12.025_bib0455","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1755-148X.2007.00433.x","article-title":"How to make a melanoma: What do we know of the primary clonal events?","volume":"21","author":"Bennett","year":"2008","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ad.2016.12.025_bib0460","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/CCO.0b013e3282f5271c","article-title":"The MAPK pathway in melanoma","volume":"20","author":"Fecher","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ad.2016.12.025_bib0465","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jmoldx.2012.09.001","article-title":"Detection of BRAF p.V600E mutations in melanomas: Comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing","volume":"15","author":"Colomba","year":"2013","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ad.2016.12.025_bib0470","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1006\/abio.1998.2978","article-title":"Analyses of secondary structures in DNA by pyrosequencing","volume":"267","author":"Ronaghi","year":"1999","journal-title":"Anal Biochem"},{"key":"10.1016\/j.ad.2016.12.025_bib0475","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1093\/clinchem\/48.12.2164","article-title":"Pyrosequencing as an alternative to single-strand conformation polymorphism analysis for detection of N-ras mutations in human melanoma metastases","volume":"48","author":"Sivertsson","year":"2002","journal-title":"Clin Chem"},{"key":"10.1016\/j.ad.2016.12.025_bib0480","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/sj.jid.5700366","article-title":"High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi","volume":"126","author":"Ichii-Nakato","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2016.12.025_bib0485","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.nbt.2012.02.002","article-title":"Co-development of a companion diagnostic for targeted cancer therapy","volume":"29","author":"Cheng","year":"2012","journal-title":"N Biotechnol"},{"key":"10.1016\/j.ad.2016.12.025_bib0490","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.5858\/arpa.2011-0505-OA","article-title":"Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma","volume":"136","author":"Anderson","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ad.2016.12.025_bib0495","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"doi-asserted-by":"crossref","unstructured":"Martin-Algarra S, Labiano T, Echeveste JI, Gomez N, Monta\u00f1ana M, Aguirre M, et al. Use of Cobas 4800 BRAF mutation test for the analysis of BRAF V600 mutations in cytological samples (CS) from metastatic melanoma (MM). J Clin Oncol. 2012; ASCO Annual Meeting Abstracts. Vol 30, No 15_suppl (May 20 Suppl), 2012: 8572.","key":"10.1016\/j.ad.2016.12.025_bib0500","DOI":"10.1200\/jco.2012.30.15_suppl.8572"},{"key":"10.1016\/j.ad.2016.12.025_bib0505","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-011-0887-y","article-title":"Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases","volume":"123","author":"Capper","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ad.2016.12.025_bib0510","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00401-011-0841-z","article-title":"Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody","volume":"122","author":"Capper","year":"2011","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ad.2016.12.025_bib0515","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/PAS.0b013e318246b527","article-title":"Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma","volume":"36","author":"Koperek","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ad.2016.12.025_bib0520","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/bjc.2016.106","article-title":"A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma","volume":"115","author":"Lo","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ad.2016.12.025_bib0525","doi-asserted-by":"crossref","first-page":"14122","DOI":"10.3390\/ijms160614122","article-title":"Circulating cell-free tumour DNA in the management of cancer","volume":"16","author":"Francis","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ad.2016.12.025_bib0530","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molonc.2015.12.008","article-title":"Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients","volume":"10","author":"Huang","year":"2016","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ad.2016.12.025_bib0535","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/path.2382","article-title":"Heterogeneity of kinase inhibitor resistance mechanisms in GIST","volume":"216","author":"Liegl","year":"2008","journal-title":"J Pathol"},{"key":"10.1016\/j.ad.2016.12.025_bib0540","first-page":"3468","article-title":"Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: Mutations occur early and persist throughout tumor progression","volume":"8","author":"Omholt","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ad.2016.12.025_bib0545","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1038\/jid.2015.229","article-title":"Intra- and inter-tumoral homogeneity of BRAF(V600E) mutations in melanoma tumors","volume":"135","author":"Riveiro-Falkenbach","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2016.12.025_bib0550","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.yexmp.2014.09.008","article-title":"Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: Implications on optimized targeted therapy","volume":"97","author":"Saroufim","year":"2014","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.ad.2016.12.025_bib0555","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.0022-202X.2005.23788.x","article-title":"BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival","volume":"125","author":"Akslen","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ad.2016.12.025_bib0560","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/PAS.0b013e318271249e","article-title":"Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions","volume":"37","author":"Busam","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ad.2016.12.025_bib0565","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1477-3163-3-6","article-title":"Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis","volume":"3","author":"Houben","year":"2004","journal-title":"J Carcinog"},{"key":"10.1016\/j.ad.2016.12.025_bib0570","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: A study based on mutation screening by pyrosequencing","volume":"16","author":"Edlundh-Rose","year":"2006","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ad.2016.12.025_bib0575","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1479-5876-2-46","article-title":"Clinical significance of BRAF mutations in metastatic melanoma","volume":"2","author":"Chang","year":"2004","journal-title":"J Transl Med"},{"key":"10.1016\/j.ad.2016.12.025_bib0580","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/bjc.2011.239","article-title":"Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success","volume":"105","author":"Sigalotti","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ad.2016.12.025_bib0585","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/jdv.12148","article-title":"BRAF mutational epidemiology in dysplastic nevi: does different solar UV radiation exposure matter?","volume":"28","author":"Saroufim","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2016.12.025_bib0590","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cam4.50","article-title":"Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases","volume":"2","author":"Niessner","year":"2013","journal-title":"Cancer Med"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731017302776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731017302776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:06:30Z","timestamp":1757552790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731017302776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0001731017302776"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2016.12.025","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concordancia mutacional de BRAF entre melanoma primario cut\u00e1neo y sus correspondientes met\u00e1stasis. Revisi\u00f3n de la evidencia actual","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2016.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 AEDV. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}